Clinical Study of Interleukin-11(Il-11)in the Treatment of Thrombocytopenia Caused by the Chemotherapy of Malignant Tumor

贾晓琳,杨丽艳,李玉芳,王意忠
DOI: https://doi.org/10.3969/j.issn.1005-8664.2007.05.010
2007-01-01
Abstract:Objective To study the clinical efficacy and side effect of IL-11 in the treatment of thrombocytopenia caused by the chemotherapy of malignant tumor.Method Fifty-one patients with malignant tumors were divided randomly into the treated group(n=27) and the control group(n=24).The treatment with IL-11(1.5mg,IH,once per day) was given once their platelet counts were lower than 50×109/L during the chemotherapy.The duration of treatment was 5-14 days,with average of 9.2 days until the platelet count increased to 100×109/L.The control group was only given intravenous infusion of platelets when necessary.Results The lowest platelet count increased significantly in the treated group after giving IL-11,which was significantly different from that in the control group.The duration of platelet count lower than 50×109/L in the treated group was also significantly shorter than that in the control group.Of the 27 cases in the treated group,9 had complete response(33.3%) and 18 had partial response(66.7%).Conclusion IL-11 is an effective,safe and economical way for the treatment of thrombocytopenia caused by the chemotherapy of malignant tumor.
What problem does this paper attempt to address?